10 results on '"Shipp, Margaret A."'
Search Results
2. Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.
- Author
-
W. Robert Liu and Shipp, Margaret A.
- Subjects
- *
HODGKIN'S disease , *CELL proliferation , *LYMPHOBLASTIC leukemia , *JAK-STAT pathway , *CHROMOSOME abnormalities - Abstract
Classical Hodgkin lymphoma (cHL) is an unusual B-cell-derived malignancy in which rare malignant Hodgkin and Reed-Sternberg (HRS) cells are surrounded by an extensive but ineffective inflammatory/immune cell infiltrate. This striking feature suggests that malignant HRS cells escape immunosurveil-lance and interact with immune cells in the cancer microenvironment for survival and growth. We previously found that cHLs have a genetic basis for immune evasion: near-unitorm copy number alterations of chromosome 9p24.1 and the associated PD-1 ligand loci. CD274/PD-L1 and PDCD1LG2/ PD-L2, and copy number-dependent increased expression of these ligands. HRS cells expressing PD-1 ligands are thought to engage PD-1 receptor-positive immune effectors in the tumor microenvironment and induce PD-1 signaling and associated immune evasion. The genetic bases of enhanced PD-1 signaling in cHL make these tumors uniquely sensitive to PD-1 blockade. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
3. Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.
- Author
-
Liu, W. Robert and Shipp, Margaret A.
- Subjects
- *
HODGKIN'S disease treatment , *HODGKIN'S disease , *CANCER cell proliferation , *CANCER treatment , *B cell lymphoma - Abstract
Classical Hodgkin lymphoma (cHL) is an unusual B-cell--derived malignancy in which rare malignant Hodgkin and Reed-Sternberg (HRS) cells are surrounded by an extensive but ineffective inflammatory/immune cell infiltrate. This striking feature suggests that malignant HRS cells escape immunosurveillance and interact with immune cells in the cancer microenvironment for survival and growth. We previously found that cHLs have a genetic basis for immune evasion: near uniform copy number alterations of chromosome 9p24.1 and the associated PD-1 ligand loci, CD274/PD-L1 and PDCD1LG2/PD-L2, and copy number--dependent increased expression of these ligands. HRS cells expressing PD-1 ligands are thought to engage PD-1 receptor--positive immune effectors in the tumor microenvironment and induce PD-1 signaling and associated immune evasion. The genetic bases of enhanced PD-1 signaling in cHL make these tumors uniquely sensitive to PD-1 blockade. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
4. The AP1-dependent secretion of galectin-1 by Reed-Sternberg cells fosters immune privilege in classical Hodgkin lymphoma.
- Author
-
Juszczynski, Przemyslaw, Jing Ouyang, Monti, Stefano, Rodig, Scott J., Takeyama, Kunihiko, Abramson, Jeremy, Wen Chen, Kutok, Jeffery L., Rabinovich, Gabriel A., and Shipp, Margaret A.
- Subjects
IMMUNOREGULATION ,IDIOTYPIC networks ,IMMUNOMODULATORS ,IR genes ,CYTOKINES ,HODGKIN'S disease - Abstract
Classical Hodgkin lymphomas (cHLs) contain small numbers of neo-plastic Reed-Sternberg (RS) cells within an extensive inflammatory infiltrate that includes abundant T helper (Th)-2 and T regulatory (T
reg ) cells. The skewed nature of the T cell infiltrate and the lack of an effective host antitumor immune response suggest that RS cells use potent mechanisms to evade immune attack. In a screen for T cell-inhibitory molecules in cHL we found that RS cells selectively overexpressed the immunoregulatory glycan-binding protein, galectin-1 (Gal1), through an AP1-dependent enhancer. In cocultures of activated T cells and Hodgkin cell lines, RNAi-mediated blockade of RS cell Gal1 increased T cell viability and restored the Th1/Th2 balance. In contrast, Gal1 treatment of activated T cells favored the secretion of Th2 cytokines and the expansion of CD4+ CD25high FOXP3+ Treg cells. These data directly implicate RS cell Gal1 in the development and maintenance of an immunosuppressive Th2/Treg -skewed microenvironment in cHL and provide the molecular basis for selective Gal1 expression in RS cells. Thus, Gal1 represents a potential therapeutic target for restoring immune surveillance in cHL. [ABSTRACT FROM AUTHOR]- Published
- 2007
- Full Text
- View/download PDF
5. High dose CHOP: A phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351.
- Author
-
Peterson, Bruce A., Johnson, Jeffrey, Shipp, Margaret A., Barcos, Maurice, Gockerman, Jon P., Canellos, George P., and For the Cancer and Leukemia Group B
- Subjects
LYMPHOMAS ,DOXORUBICIN ,HODGKIN'S disease ,TOXICITY testing ,DRUG dosage ,ANTINEOPLASTIC agents ,BLOOD platelet disorders - Abstract
Cyclophosphamide and doxorubicin, two important drugs in the treatment of lymphoma, exhibit a relationship between dose and fractional cell kill, and because of their toxicity profiles, they are candidates for significant dose escalation. We performed a phase II trial to determine the response rate, toxicity, and feasibility of escalated doses of both drugs as part of high dose CHOP in diffuse aggressive lymphoma. Patients who had advanced, previously untreated diffuse aggressive lymphomas (IWF E-H) and an International Prognostic Index of intermediate to high risk were eligible. Treatment was cyclophosphamide 2 gm/m2/day intravenously on Days 1 and 2 (total cycle dose 4 gm/m2), doxorubicin 35 mg/m2/day as a continuous infusion on Days 1 and 2 (total 70 mg/m2), vincristine 1.4 mg/m2 (maximum 2 mg) on Day 1 and prednisone 100 mg/day orally on Days 1 - 5 repeated every 3 weeks for a total of four cycles. G-CSF, prophylactic antibiotics, and mesna were provided. A total of 99 patients were enrolled; 98 received therapy. Major toxicities were Grade 4 neutropenia and thrombocytopenia occurring in 97% and 92%, respectively. Serious infections occurred in 53%. Treatment-related mortality was 2%. The overall response rate is 85%, and two-year failure free and overall survival are 39% and 64%, respectively. Persistent or relapsed lymphoma was the overwhelming cause of death. Six patients have developed AML or MDS. In view of the substantial toxicity accompanying high dose CHOP, the observed outcome suggests that its efficacy is not sufficient to make further study feasible. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
6. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
- Author
-
Younes, Anas, Santoro, Armando, Shipp, Margaret, Zinzani, Pier Luigi, Timmerman, John M, Ansell, Stephen, Armand, Philippe, Fanale, Michelle, Ratanatharathorn, Voravit, Kuruvilla, John, Cohen, Jonathon B, Collins, Graham, Savage, Kerry J, Trneny, Marek, Kato, Kazunobu, Farsaci, Benedetto, Parker, Susan M, Rodig, Scott, Roemer, Margaretha G M, and Ligon, Azra H
- Subjects
- *
HODGKIN'S disease , *STEM cell transplantation , *BLOCKING antibodies , *DISEASE relapse , *DISEASE progression , *NEUTROPENIA , *ANTINEOPLASTIC agents , *HODGKIN'S disease treatment , *THERAPEUTIC use of monoclonal antibodies , *AUTOGRAFTS , *CANCER relapse , *CLINICAL trials , *COMBINED modality therapy , *COMPARATIVE studies , *HEMATOPOIETIC stem cell transplantation , *IMMUNOGLOBULINS , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *PROGNOSIS , *RESEARCH , *RESEARCH funding , *SURVIVAL , *TUMOR classification , *EVALUATION research , *SALVAGE therapy , *CANCER treatment - Abstract
Background: Malignant cells of classical Hodgkin's lymphoma are characterised by genetic alterations at the 9p24.1 locus, leading to overexpression of PD-1 ligands and evasion of immune surveillance. In a phase 1b study, nivolumab, a PD-1-blocking antibody, produced a high response in patients with relapsed and refractory classical Hodgkin's lymphoma, with an acceptable safety profile. We aimed to assess the clinical benefit and safety of nivolumab monotherapy in patients with classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin.Methods: In this ongoing, single-arm phase 2 study, adult patients (aged ≥18 years) with recurrent classical Hodgkin's lymphoma who had failed to respond to autologous stem-cell transplantation and had either relapsed after or failed to respond to brentuximab vedotin, and with an Eastern Cooperative Oncology Group performance status score of 0 or 1, were enrolled from 34 hospitals and academic centres across Europe and North America. Patients were given nivolumab intravenously over 60 min at 3 mg/kg every 2 weeks until progression, death, unacceptable toxicity, or withdrawal from study. The primary endpoint was objective response following a prespecified minimum follow-up period of 6 months, assessed by an independent radiological review committee (IRRC). All patients who received at least one dose of nivolumab were included in the primary and safety analyses. This trial is registered with ClinicalTrials.gov, number NCT02181738.Findings: Among 80 treated patients recruited between Aug 26, 2014, and Feb 20, 2015, the median number of previous therapies was four (IQR 4-7). At a median follow-up of 8·9 months (IQR 7·8-9·9), 53 (66·3%, 95% CI 54·8-76·4) of 80 patients achieved an IRRC-assessed objective response. The most common drug-related adverse events (those that occurred in ≥15% of patients) included fatigue (20 [25%] patients), infusion-related reaction (16 [20%]), and rash (13 [16%]). The most common drug-related grade 3 or 4 adverse events were neutropenia (four [5%] patients) and increased lipase concentrations (four [5%]). The most common serious adverse event (any grade) was pyrexia (three [4%] patients). Three patients died during the study; none of these deaths were judged to be treatment related.Interpretation: Nivolumab resulted in frequent responses with an acceptable safety profile in patients with classical Hodgkin's lymphoma who progressed after autologous stem-cell transplantation and brentuximab vedotin. Therefore, nivolumab might be a new treatment option for a patient population with a high unmet need. Ongoing follow-up will help to assess the durability of response.Funding: Bristol-Myers Squibb. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
7. A Predictive Model for Non-Hodgkin's Lymphoma.
- Author
-
Shipp, Margaret A. and Harrington, David P.
- Subjects
- *
LETTERS to the editor , *HODGKIN'S disease - Abstract
A response by Margaret A. Shipp and David P. Harrington to several letters to the editor about their article regarding a predictive model for non-Hodgkin's lymphoma, that was published in the September 30, 1993 issue is presented.
- Published
- 1994
- Full Text
- View/download PDF
8. Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell--rich and exhausted T-effector microenvironment.
- Author
-
Cader, Fathima Zumla, Schackmann, Ron C. J., Xihao Hu, Wienand, Kirsty, Redd, Robert, Chapuy, Bjoern, Jing Ouyang, Paul, Nicole, Gjini, Evisa, Lipschitz, Mikel, Armand, Philippe, Wu, David, Fromm, Jonathan R., Neuberg, Donna, Liu, X. Shirley, Rodig, Scott J., and Shipp, Margaret A.
- Subjects
- *
HODGKIN'S disease , *IMMUNE response , *IMMUNE system , *T cells , *MAJOR histocompatibility complex - Abstract
In classical Hodgkin lymphoma (cHL), the host antitumor immune response is ineffective. Hodgkin Reed-Sternberg (HRS) cells have multifaceted mechanisms to evade the immune system, including 9p24.1/CD274(PD-L1)/PDCD1LG2(PD-L2) genetic alterations, overexpression of PD-1 ligands, and associated T-cell exhaustion and additional structural bases of aberrant antigen presentation. The clinical success of PD-1 blockade in cHL suggests that the tumor microenvironment (TME) contains reversibly exhausted T effector cells (Teffs). However, durable responses are observed in patients with β2-microglobulin/major histocompatibility complex (MHC) class I loss on HRS cells, raising the possibility of non-CD81 T cell--mediated mechanisms of efficacy of PD-1 blockade. These observations highlight the need for a detailed analysis of the cHL TME. Using a customized time-of-flight mass cytometry panel, we simultaneously assessed cell suspensions from diagnostic cHL biopsies and control reactive lymph node/tonsil (RLNT) samples. Precise phenotyping of immune cell subsets revealed salient differences between cHLs and RLNTs. The TME in cHL is CD4+ T-cell rich, with frequent loss of MHC class I expression on HRS cells. In cHLs, we found concomitant expansion of T helper 1 (Th1)-polarized Teffs and regulatory T cells (Tregs). The cHL Th1 Tregs expressed little or no PD-1, whereas the Th1 Teffs were PD-1+. The differential PD-1 expression and likely functional Th1-polarized CD4+ Tregs and exhausted Teffs may represent complementary mechanisms of immunosuppression in cHL. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
9. Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.
- Author
-
Carey, Christopher D., Gusenleitner, Daniel, Lipschitz, Mikel, Roemer, Margaretha G. M., Stack, Edward C., Gjini, Evisa, Xihao Hu, Redd, Robert, Freeman, Gordon J., Neuberg, Donna, Hodi, F. Stephen, Liu, Xiaole Shirley, Shipp, Margaret A., and Rodig, Scott J.
- Subjects
- *
HODGKIN'S disease , *MACROPHAGES , *TUMOR microenvironment , *IMMUNOFLUORESCENCE , *CELL death - Abstract
Signaling between programmed cell death protein 1 (PD-1) and the PD-1 ligands (PD-L1, PD-L2) is essential for malignant Hodgkin Reed-Sternberg (HRS) cells to evade antitumor immunity in classical Hodgkin lymphoma (cHL). Copy number alterations of 9p24.1/ CD274(PD-L1)/PDCD1LG2(PD-L2) contribute to robust PD-L1 and PD-L2 expression by HRS cells. PD-L1 is also expressed by nonmalignant tumor-associated macrophages (TAMs), but the relationships among PD-L11 HRS cells, PD-L11 TAMs, and PD-11 T cells remain undefined. We used multiplex immunofluorescence and digital image analysis to examine the topography of PD-L11 and PD-11 cells in the tumor microenvironment (TME) of cHL.Wefind that the majority of PD-L1 in theTMEis expressed by the abundant PD-L11 TAMs, which physically colocalize with PD-L11 HRS cells in a microenvironmental niche. PD-L11 TAMs are enriched for contacts with T cells, and PD-L11 HRS cells are enriched for contacts with CD41 T cells, a subset of which are PD-11. Our data define a unique topology of cHL in which PD-L11 TAMs surround HRS cells and implicate CD41 T cells as a target of PD-1 blockade. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
10. Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphoma.
- Author
-
Jing Ouyang, Plütschow, Annette, von Strandmann, Elke Pogge, Reiners, Katrin S., Ponader, Sabine, Rabinovich, Gabriel A., Neuberg, Donna, Engert, Andreas, and Shipp, Margaret A.
- Subjects
- *
GALECTINS , *HODGKIN'S disease , *CARBOHYDRATE-binding proteins , *IMMUNE response , *T helper cells - Abstract
Galectin-l (Gall) is a member of a highly conserved family of carbohydrate-binding proteins. It modulates innate and adaptive immune responses and fosters tumor-immune escape. Hodgkin lymphoma (HL) Reed-Sternberg cells overexpress and secrete Gal1, which selectively kills T helper (Th)l and Th17 cells and cytotoxic T cells and promotes the immunosuppressive Th2/regulatory T-cell-predominant HL microenvironment. We developed a sandwich enzyme-linked immunosorbent assay and assessed serum Gall levels in 293 newly diagnosed, previously untreated patients with classical HL (cHL) enrolled in 3 risk- adapted clinical trials. Serum Gal1 levels were significantly higher in patients with cHL than in normal controls (P < .0001). Gall serum levels also increased with Ann Arbor stage (P = .012), areas of nodal involvement (P< .0001), and the International Prognostic Score (2-7, P = .019). We conclude that Gall serum levels are significantly associated with tumor burden and related clinical features in newly diagnosed cHL patients. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.